{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-086651","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2026-07-24T20:15:40+00:00","discovered_at":"2026-07-24T20:17:00.337943+00:00","generated_at":"2026-07-24T20:17:29.736642+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Acura receives $200K loan from AD Pharma; warns of possible shutdown without more funding by mid-August","bullets":["New $200K loan from Abuse Deterrent Pharma increases principal to $10.9M, bearing 5.25% interest.","Accrued interest ~$1.2M as of July 17, 2026; overdue amounts bear 7.5% interest.","Without additional financing by mid-August 2026, company will scale back operations, furlough/lay off employees, or seek bankruptcy.","Failure to secure funding could result in complete loss of shareholder value.","Loan proceeds used for day-to-day operations; no assurance of further financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-086651","json":"https://secwatch.observer/filing/0001104659-26-086651.json","markdown":"https://secwatch.observer/filing/0001104659-26-086651.md","text":"https://secwatch.observer/filing/0001104659-26-086651.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465926086651/0001104659-26-086651-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465926086651/tm2621293d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-24T20:17:29.736642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}